Navigation Links
First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan

Unprecedented Evidence for the Effectiveness of Hypertension Treatment Valsartan in Preventing Cardiovascular Events in Japanese Patients

TOKYO, April 26, 2007 /Xinhua-PRNewswire/ -- The clinical outcomes of the JIKEI HEART Study, the large-scale clinical trial headed by the Jikei University School of Medicine, was today published in the internationally renowned medical journal The Lancet. The study, involving more than 3,000 patients, is one of the largest cardiovascular intervention trials conducted in a Japanese population under realistic clinical settings. It also is the first large- scale study evaluating the benefits of the ARB, valsartan, in Japanese patients.

In the study, valsartan was added to conventional therapy to control blood pressure and protect against cardiovascular events and stroke. The results showed significant benefit with the use of valsartan, including a 39% decrease in cardiovascular events and a 40% decrease in stroke compared to conventional non-ARB therapy. Initiated in 2001, the JIKEI HEART Study was terminated earlier than anticipated at the request of the Data and Safety Monitoring Board due to superior outcomes for the valsartan group over the control group.

"Treatment of hypertension needs to account for blood pressure control but also should take into account the prevention of cardiovascular diseases over an extended period," said Seibu Mochizuki, M.D., PhD, formerly of Jikei University School of Medicine, chief investigator of the JIKEI HEART Study. "In the JIKEI HEART Study we accomplished both -- we achieved the lowest blood pressure value ever set in a morbidity/mortality outcomes trial and saw tremendous benefit for the valsartan arm in reducing the risk of cardiovascular events as well as stroke. Because of this, valsartan will play an important role in treating hypertension as it has been shown to lower blood pressure while being highly protective of end o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:7/3/2015)... July 4, 2015 A global ... hypertension, diabetes and thyroid disorders in Central and ... platforms and a major conference dedicated to these diseases. ... Manage Diabetes Online , Manage Hypertension Online ... and operated by EXCEMED - combine the ...
(Date:7/3/2015)... -- Obsidian HDS, the developer of PharmaShine ( www.pharmashine.com ... of data on pharmaceutical and device industry payments to ... 2014 Open Payments General and Research data released by ... data disclosed on Open Payments for 2014 includes information ... $6.49 billion and is the largest public disclosure of ...
(Date:7/2/2015)... , July 2, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... shares have been approved for listing and trading on the ... ESSA will begin trading on NASDAQ on July 9, 2015.  ... Exchange under the symbol "EPI". As a result ... each of the Company,s outstanding special warrants issued on January ...
Breaking Medicine Technology:Combating Three Major Chronic Diseases in Central and South-East Asia With Medical Education 2New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4
... 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... emerging leader in the development, assembly, marketing and sale ... today announced that it was granted three new patents ... of China ("SIPO"). The patent awards were related to ...
... Cellular Dynamics International (CDI) today announced the online publication ... demonstrating for the first time a methodology for researchers ... blood samples through the creation of induced pluripotent stem ... B-cell lines reprogrammed to EBV-free induced pluripotent stem cells," ...
Cached Medicine Technology:Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3Cellular Dynamics International Unlocks the Potential of Banked Blood Samples 2
(Date:7/5/2015)... ... July 05, 2015 , ... Doctors at the Swedish Cancer ... combination may one day change the outlook for people with pleural mesothelioma. Surviving Mesothelioma ... , Researchers report that five mesothelioma patients treated with 25Gy of radiation over ...
(Date:7/4/2015)... New York, NY (PRWEB) , ... July 04, 2015 , ... ... suggest that 15% of chronic pain sufferers have pain located in the neck. Another ... referred from the neck. Chiropractic literature suggests that 45% of American workers ...
(Date:7/3/2015)... ... July 04, 2015 , ... The Harvest Hope Food Bank will hopefully be ... AlignLife offices in the area of Greenville SC are making it their mission ... by patients only. They are asking for donations from the public as well. As part ...
(Date:7/3/2015)... , ... July 03, 2015 ... ... the sessions and speaker lineup for its 2015 Annual Conference , ... August 6-8, 2015 at the Renaissance Orlando at SeaWorld in Orlando, Florida. ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. ... has been retained to lead a national president recruitment for Regional ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3
... Dec. 8 BHR Pharma, LLC (BHR) ... application with the U.S. Food and Drug Administration (FDA) for its ... year, the company made public plans to initiate a global, Phase ... the safety and effectiveness of BHR-100 as a neuroprotective agent for ...
... , CINCINNATI and JACKSONVILLE, Fla., Dec. 8 LCA-Vision ... correction services under the Lasik Plus ® brand, announced today that ... free Lasik Plus® corrective vision surgery to U.S. military veterans ... Warrior Project, and is doing its part to enhance the lives ...
... , SAN DIEGO, Dec. 8 PROVERI, Inc. ... a winner of the annual New England Venture Summit Top Innovator ... recognizes those that play a leading role in innovation for the ... winners, Waldemar Lernhardt, Ph.D., President and Chief Executive Officer of PROVERI, ...
... , ANN ARBOR, Mich., Dec. 8 ... bench-top flow cytometer systems, today announced the 2009 recipients of ... free Accuri C6 Flow Cytometer® System each year to two ... Europe, who propose innovative uses of flow cytometry. Explicitly ...
... , LONDON, ... both structural reform and unavailability of resources as the region,s working ... This calls for the introduction of new schemes in healthcare that ... ageing population. The involvement of Information and Communication Technology (ICT) in ...
... ... UK’s premier centre for Integrated Medicine, launches Regenerus, the most comprehensive anti-ageing assessment and ... ... Secretary, Andy Burnham, published the results of a Department of Health Survey that reveals ...
Cached Medicine News:Health News:BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment 2Health News:LCA-Vision Joins Forces With the Wounded Warrior Project to Give the Gift of Enhanced Vision to Wounded American Heroes 2Health News:PROVERI, Inc. Named a Top Innovator Winner 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 3Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 4Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
The Uro San® Plus male external catheter is a latex catheter with a double-sided adhesive and Shield Skin Protective Dressing....
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
Medicine Products: